FOLFIRINOX + RT for Pancreatic Cancer
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of a therapy to learn whether the therapy works in treating a specific cancer. "Investigational" means that the therapy is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if therapy is effective for treating different types of cancer. Proton beam radiation therapy is an FDA (U.S. Food and Drug Administration) approved radiation delivery system.
Proton beam radiation therapy is known to spare surrounding normal tissues from radiation as it delivers less radiation beyond the area of the target tissues. This may reduce side effects that patients would normally experience with standard (photon) radiation therapy, which tends to include more normal tissue along with tumor target tissue.
Researchers in the laboratory have discovered that there are pathways inside the cells that can lead to growth and survival of the tumor. The chemotherapy drugs FOLFIRINOX and capecitabine are targeted towards blocking the pathways that allow cancer cells to divide, and may result in the tumor shrinking in size.
In this research study, the investigators are looking to determine if proton beam radiation in combination with FOLFIRINOX and capecitabine is effective in controlling the growth of your cancer.
Radiation: Proton Radiation
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy With Proton Beam for Borderline-Resectable Pancreatic Cancer|
- Rate of Resection [ Time Frame: 2 years ] [ Designated as safety issue: No ]To determine the rate of R0 resection of patients with borderline-resectable adenocarcinoma of the head of the pancreas, along with borderline-resectable and resectable adenocarcinoma of the body and tail of the pancreas
- Progression-Free Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]To determine the progression-free survival of patients who recieve preoperative FOLFIRINOX and preoperative short-course proton therapy
- Overall Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]To determine overall survival in patients treated with preopertive FOLFIRINOX and proton beam radiation therapy
- Toxicity rate [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]To determine the frequency and severity of toxicities of FOLFIRINOX+proton beam radiation therapy in patients with pancreatic cancer
- Surgical Morbidity [ Time Frame: 2 years ] [ Designated as safety issue: No ]To determine the surgical morbidity in patients undergoing pancreaticoduodenectomy or distal pancreatectomy who received preoperative FOLFIRINOX and preoperative proton therapy
- 30 Day Post-operative Mortality [ Time Frame: 2 years ] [ Designated as safety issue: No ]To determine 30 day post-operative mortality after pancraeticoduodenectomy or distal pancreatectomy in patients who receive preoperative FOLFIRINOX and proton therapy
- Rate of Pathologic Downstaging [ Time Frame: 2 years ] [ Designated as safety issue: No ]To dermine the rate of pathologic downstaging of FOLFIRINOX+short course proton therapy for patients with pancreatic cancer
- Local Control Rates [ Time Frame: 2 years ] [ Designated as safety issue: No ]To determine local control rates with FOLFIRINOX+preoperative proton therapy
- Correlation of Mutational Analysis Biomarkers [ Time Frame: 2 years ] [ Designated as safety issue: No ]To correlate mutational analysis biomarkers (SNaPSHOT assay) with response to treatment
|Study Start Date:||May 2012|
|Estimated Primary Completion Date:||May 2015 (Final data collection date for primary outcome measure)|
Experimental: Treatment Arm
All participants will receive the FOLFIRINOX regimen, followed by capecitabine and proton radiation therapy.
Four-14 day cycles
Other Names:Drug: Capecitabine
Orally, for 10 daysRadiation: Proton Radiation
Five daysProcedure: Surgery
1-4 weeks after completion of capecitabine therapy
The treatment plan will begin with four cycles (8 weeks) of FOLFIRINOX. Each cycle is 14 days long. You will receive FOLFIRINOX therapy on days 1, 2 and 3 of each of the four cycles. The FOLFIRINOX treatment is broken up into three different drugs. 5-FU will be administered over two hours on day one of each cycle, and then continuously with a pump for days 2 and 3. Oxaliplatin will be delivered by intravenous (infusion)over 120 minutes. Irinotecan will be given by IV for 90 minutes. All parts of this treatment will be received as an outpatient.
You will take tablets of capecitabine by mouth for a total of 10 days (Monday through Friday) during the two weeks after your FOLFIRINOX treatment.
You will be given a drug diary for capecitabine which contains instructions on how to take the drug.
Proton radiation: You will receive proton radiation treatment for five days (Monday through Friday) after your FOLFIRINOX treatment, during the time of your capecitabine treatment. You will also be assessed at least once during this treatment course for any side effects you may be experiencing.
You will receive study radiation treatment as an outpatient at the Francis H. Burr Proton Center. This center is located at the Massachusetts General Hospital Surgery is expected to occur approximately one to four weeks after completion of capecitabine therapy.
After your surgery, you will continue with four additional months of therapy with FOLFIRINOX if you are well enough to receive it. You will also have follow up visits after surgery every 3 months for as long as your tumor does not grow.
|Contact: Theodore Hong, MDfirstname.lastname@example.org|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Theodore Hong, MD 617-724-1700 email@example.com|
|Principal Investigator: Theodore Hong, MD|
|Principal Investigator:||Theodore S Hong, M.D.||Massachusetts General Hospital|